Effect of PAP Treatment on Glycemic Control in Patients with Type 2 Diabetes
Enrollment for this study is complete.
Purpose
Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality. Research indicates that the prevalence of OSA is increased in diabetic patients when compared with normoglycemic patients and that OSA is independently associated with type 2 diabetes. Further research suggests that effective treatment of OSA with continuous positive airway pressure (CPAP) improves insulin responsiveness in both non-diabetic OSA patients and diabetic-OSA patients. ResMed is conducting a clinical trial to evaluate the impact of CPAP therapy on glycemic control in type 2 diabetic patients with OSA. Patients with OSA will be randomized into one of two groups: either a CPAP treatment group or a non-treatment group. Patients will be followed for 6 months with collection of various lab tests to assess glycemic control.
Condition |
Intervention |
Diabetes Mellitus Type 2 |
Device:
Positive airway pressure therapy |
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes and Obstructive Sleep Apnea
Primary Outcome Measures: Assessment of the effectiveness of CPAP in improving glycemic control in type 2 diabetic patients with newly diagnosed OSA, through evaluation of HbA1c.